NCT05725798View on ClinicalTrials.gov

Perioperative Sitagliptin Medication for Reduction of the Inflammatory Response Associated With Cardiopulmonary Bypass

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

May 1, 2023

Study Completion Date

August 1, 2023

Conditions

Systemic Inflammatory Response Syndrome

Interventions

DRUG

Sitagliptin

Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.

Trial Locations (1)

48147

University Hospital Münster, Münster

All Listed Sponsors

lead

University Hospital Muenster

OTHER